Home » Stocks » DURECT Corporation

DURECT Corporation (DRRX)

Stock Price: $2.30 USD -0.04 (-1.71%)
Updated Aug 11, 2020 4:00 PM EDT - Market closed
After-hours: $2.40 +0.10 (4.35%) Aug 11, 7:58 PM

Stock Price Chart

Key Info

Market Cap 461.33M
Revenue (ttm) 50.07M
Net Income (ttm) -1.83M
Shares Out 200.58M
EPS (ttm) -0.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Aug 11, 2020
Last Price $2.30
Previous Close $2.34
Change ($) -0.04
Change (%) -1.71%
Day's Open 2.40
Day's Range 2.28 - 2.41
Day's Volume 1,116,336
52-Week Range 0.95 - 3.95

More Stats

Market Cap 461.33M
Enterprise Value 436.62M
Earnings Date (est) Nov 9, 2020
Ex-Dividend Date n/a
Shares Outstanding 200.58M
Float 177.72M
EPS (basic) -0.02
EPS (diluted) -0.01
FCF / Share 0.01
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield 0.20%
Payout Ratio n/a
Shares Short 15.52M
Short Ratio 4.70
Short % of Float 7.37%
Beta 2.05
PE Ratio n/a
Forward PE n/a
P/FCF Ratio 509.19
PS Ratio 9.21
PB Ratio 12.86
Revenue 50.07M
Operating Income -530,000
Net Income -1.83M
Free Cash Flow 906,000
Net Cash 24.71M
Net Cash / Share 0.12
Gross Margin -10.56%
Operating Margin -1.06%
Profit Margin -3.70%
FCF Margin 1.81%
ROA -0.97%
ROE -6.18%
ROIC n/a
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$5.75*
(150.00% upside)
Low
5.00
Current: $2.30
High
7.00
Target: 5.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016201520142013201220112010
Revenue29.5618.5649.1714.0319.1219.4015.3353.0733.4931.59
Revenue Growth59.25%-62.25%250.59%-26.66%-1.43%26.59%-71.12%58.48%6%-
Gross Profit25.4214.3042.548.7415.2213.7210.4948.4228.7727.32
Operating Income-19.15-23.62-2.24-32.36-20.66-21.00-21.1616.06-18.85-23.84
Net Income-20.58-25.32-3.70-34.51-22.66-22.11-21.4516.20-18.77-22.90
Shares Outstanding17816014513311911210388.4387.4186.87
Earnings Per Share-0.12-0.16-0.03-0.26-0.19-0.20-0.210.18-0.21-0.26
Operating Cash Flow11.10-19.75-1.34-27.29-20.83-14.56-15.45-13.45-17.397.76
Capital Expenditures-0.16-0.09-0.07-0.15-0.23-0.20-0.07-0.29-2.47-0.26
Free Cash Flow10.95-19.84-1.41-27.44-21.06-14.76-15.52-13.74-19.857.51
Cash & Equivalents64.6734.3236.7625.0029.0432.7020.5928.5328.8045.51
Total Debt26.8220.5320.8619.8519.6819.82----
Net Cash / Debt37.8513.7815.905.159.3612.8720.5928.5328.8045.51
Assets86.0250.0053.1140.5146.7750.0840.8245.9449.2067.56
Liabilities63.1630.0031.6332.1731.8931.5710.109.6045.7253.07
Book Value22.8620.0021.498.3414.8818.5230.7236.333.4814.49
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name DURECT Corporation
Country United States
Employees 93
CEO James E. Brown

Stock Information

Ticker Symbol DRRX
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers - Other
Unique Identifier NASDAQ: DRRX
IPO Date September 28, 2000

Description

DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase I and II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Zogenix, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.